Theraclion Balance Sheet Health

Financial Health criteria checks 2/6

Theraclion has a total shareholder equity of €-114.0 and total debt of €7.6M, which brings its debt-to-equity ratio to -6651015.8%. Its total assets and total liabilities are €11.5M and €11.5M respectively.

Key information

-6,651,015.79%

Debt to equity ratio

€7.58m

Debt

Interest coverage ration/a
Cash€4.17m
Equity-€114.00
Total liabilities€11.47m
Total assets€11.47m

Recent financial health updates

Recent updates

We Think Theraclion (EPA:ALTHE) Has A Fair Chunk Of Debt

Nov 20
We Think Theraclion (EPA:ALTHE) Has A Fair Chunk Of Debt

Does Theraclion (EPA:ALTHE) Have A Healthy Balance Sheet?

Nov 26
Does Theraclion (EPA:ALTHE) Have A Healthy Balance Sheet?

Financial Position Analysis

Short Term Liabilities: ALTHE has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ALTHE has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ALTHE has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ALTHE's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALTHE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALTHE has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 8.4% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 22:44
End of Day Share Price 2025/05/23 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Theraclion SA is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Fanny MeindreCIC Market Solutions (ESN)
Fanny MeindreCIC Market Solutions (ESN)
Martial DescouturesInvest Securities